Titan Pharmaceuticals, Inc. (TTNP)
USD 3.75
(-2.6%)
USD 3.75
(-2.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.56 Million USD | 45.28% |
| 2022 | -10.17 Million USD | -25.43% |
| 2021 | -8.11 Million USD | 60.85% |
| 2020 | -20.72 Million USD | -28.83% |
| 2019 | -16.08 Million USD | -78.31% |
| 2018 | -9.02 Million USD | 36.93% |
| 2017 | -14.3 Million USD | -378.62% |
| 2016 | 5.13 Million USD | 145.53% |
| 2015 | -11.27 Million USD | -369.37% |
| 2014 | -2.4 Million USD | -124.75% |
| 2013 | 9.71 Million USD | 163.97% |
| 2012 | -15.18 Million USD | 0.15% |
| 2011 | -15.2 Million USD | -122.46% |
| 2010 | -6.83 Million USD | -16.11% |
| 2009 | -5.88 Million USD | 76.85% |
| 2008 | -25.43 Million USD | -44.1% |
| 2007 | -17.64 Million USD | -12.14% |
| 2006 | -15.73 Million USD | 29.94% |
| 2005 | -22.46 Million USD | 13.62% |
| 2004 | -26 Million USD | 13.0% |
| 2003 | -29.88 Million USD | -6.06% |
| 2002 | -28.18 Million USD | -61.37% |
| 2001 | -17.46 Million USD | 7.05% |
| 2000 | -18.78 Million USD | -66.27% |
| 1999 | -11.3 Million USD | -6.6% |
| 1998 | -10.6 Million USD | -1866.67% |
| 1997 | 600 Thousand USD | 104.65% |
| 1996 | -12.9 Million USD | -10.26% |
| 1995 | -11.7 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.09 Million USD | -97.45% |
| 2024 Q1 | -1.06 Million USD | 46.19% |
| 2023 Q1 | -1.65 Million USD | 35.58% |
| 2023 Q4 | -1.97 Million USD | -482.84% |
| 2023 Q2 | -1.58 Million USD | 4.05% |
| 2023 Q3 | -338 Thousand USD | 78.69% |
| 2023 FY | -5.56 Million USD | 45.28% |
| 2022 Q2 | -2.48 Million USD | 2.32% |
| 2022 Q4 | -2.56 Million USD | 2.73% |
| 2022 Q3 | -2.63 Million USD | -6.29% |
| 2022 FY | -10.17 Million USD | -25.43% |
| 2022 Q1 | -2.54 Million USD | -0.04% |
| 2021 Q2 | -1.68 Million USD | 36.39% |
| 2021 Q1 | -2.64 Million USD | 14.39% |
| 2021 Q3 | -1.91 Million USD | -13.99% |
| 2021 Q4 | -2.54 Million USD | -32.64% |
| 2021 FY | -8.11 Million USD | 60.85% |
| 2020 Q4 | -3.08 Million USD | 37.45% |
| 2020 Q3 | -4.93 Million USD | -6.27% |
| 2020 FY | -20.72 Million USD | -28.83% |
| 2020 Q2 | -4.64 Million USD | 16.89% |
| 2020 Q1 | -5.58 Million USD | -41.69% |
| 2019 Q4 | -3.94 Million USD | -40.6% |
| 2019 Q1 | -4.51 Million USD | -28.91% |
| 2019 FY | -16.08 Million USD | -78.31% |
| 2019 Q2 | -5.19 Million USD | -15.05% |
| 2019 Q3 | -2.8 Million USD | 46.07% |
| 2018 FY | -9.02 Million USD | 36.93% |
| 2018 Q2 | -869 Thousand USD | 66.64% |
| 2018 Q1 | -2.6 Million USD | 28.83% |
| 2018 Q4 | -3.5 Million USD | -71.34% |
| 2018 Q3 | -2.04 Million USD | -135.33% |
| 2017 Q3 | -4.19 Million USD | -21.44% |
| 2017 FY | -14.3 Million USD | -378.62% |
| 2017 Q4 | -3.66 Million USD | 12.67% |
| 2017 Q1 | -3 Million USD | -29.14% |
| 2017 Q2 | -3.45 Million USD | -14.84% |
| 2016 Q1 | -1.84 Million USD | 19.53% |
| 2016 Q3 | -2.62 Million USD | -121.97% |
| 2016 FY | 5.13 Million USD | 145.53% |
| 2016 Q4 | -2.32 Million USD | 11.18% |
| 2016 Q2 | 11.92 Million USD | 746.15% |
| 2015 Q3 | -1.8 Million USD | 20.78% |
| 2015 Q1 | -4.89 Million USD | -935.31% |
| 2015 Q4 | -2.29 Million USD | -26.95% |
| 2015 FY | -11.27 Million USD | -369.37% |
| 2015 Q2 | -2.28 Million USD | 53.42% |
| 2014 Q3 | 716 Thousand USD | 185.04% |
| 2014 Q2 | -842 Thousand USD | 53.33% |
| 2014 Q1 | -1.8 Million USD | -763.16% |
| 2014 Q4 | -473 Thousand USD | -166.06% |
| 2014 FY | -2.4 Million USD | -124.75% |
| 2013 FY | 9.71 Million USD | 163.97% |
| 2013 Q4 | -209 Thousand USD | 81.75% |
| 2013 Q3 | -1.14 Million USD | -122.61% |
| 2013 Q2 | 5.06 Million USD | -15.61% |
| 2013 Q1 | 6 Million USD | 2250.9% |
| 2012 FY | -15.18 Million USD | 0.15% |
| 2012 Q4 | -279 Thousand USD | 96.52% |
| 2012 Q3 | -8.01 Million USD | -364.79% |
| 2012 Q2 | -1.72 Million USD | 66.61% |
| 2012 Q1 | -5.16 Million USD | -78.16% |
| 2011 FY | -15.2 Million USD | -122.46% |
| 2011 Q2 | -6.98 Million USD | -54.9% |
| 2011 Q3 | -804 Thousand USD | 88.5% |
| 2011 Q4 | -2.89 Million USD | -260.45% |
| 2011 Q1 | -4.51 Million USD | -4.95% |
| 2010 Q4 | -4.29 Million USD | -1019.53% |
| 2010 FY | -6.83 Million USD | -16.11% |
| 2010 Q3 | -384 Thousand USD | 79.2% |
| 2010 Q2 | -1.84 Million USD | -505.25% |
| 2010 Q1 | -305 Thousand USD | 79.22% |
| 2009 Q3 | -1.59 Million USD | 8.18% |
| 2009 Q4 | -1.46 Million USD | 7.85% |
| 2009 FY | -5.88 Million USD | 76.85% |
| 2009 Q1 | -1.09 Million USD | 82.22% |
| 2009 Q2 | -1.73 Million USD | -59.17% |
| 2008 Q4 | -6.13 Million USD | -3.9% |
| 2008 FY | -25.43 Million USD | -44.1% |
| 2008 Q1 | -5.72 Million USD | 7.92% |
| 2008 Q2 | -7.68 Million USD | -34.22% |
| 2008 Q3 | -5.9 Million USD | 23.21% |
| 2007 FY | -17.64 Million USD | -12.14% |
| 2007 Q4 | -6.21 Million USD | -43.76% |
| 2007 Q3 | -4.32 Million USD | -22.35% |
| 2007 Q2 | -3.53 Million USD | 1.09% |
| 2007 Q1 | -3.57 Million USD | -9.4% |
| 2006 Q2 | -3.42 Million USD | 27.18% |
| 2006 Q1 | -4.7 Million USD | -16.26% |
| 2006 Q4 | -3.26 Million USD | 24.75% |
| 2006 FY | -15.73 Million USD | 29.94% |
| 2006 Q3 | -4.34 Million USD | -26.68% |
| 2005 Q1 | -6.29 Million USD | 19.26% |
| 2005 Q4 | -4.04 Million USD | 36.55% |
| 2005 FY | -22.46 Million USD | 13.62% |
| 2005 Q3 | -6.37 Million USD | -11.08% |
| 2005 Q2 | -5.74 Million USD | 8.8% |
| 2004 FY | -26 Million USD | 13.0% |
| 2004 Q2 | -5.55 Million USD | 12.94% |
| 2004 Q4 | -7.79 Million USD | -24.37% |
| 2004 Q1 | -6.38 Million USD | 39.28% |
| 2004 Q3 | -6.27 Million USD | -12.87% |
| 2003 Q3 | -6.16 Million USD | 7.66% |
| 2003 Q4 | -10.5 Million USD | -70.35% |
| 2003 FY | -29.88 Million USD | -6.06% |
| 2003 Q2 | -6.68 Million USD | -2.31% |
| 2003 Q1 | -6.53 Million USD | 26.66% |
| 2002 Q2 | -7.03 Million USD | -42.06% |
| 2002 Q1 | -4.95 Million USD | 21.73% |
| 2002 Q4 | -8.9 Million USD | -22.04% |
| 2002 FY | -28.18 Million USD | -61.37% |
| 2002 Q3 | -7.29 Million USD | -3.75% |
| 2001 Q4 | -6.32 Million USD | -32.11% |
| 2001 Q3 | -4.78 Million USD | -161.01% |
| 2001 FY | -17.46 Million USD | 7.05% |
| 2001 Q2 | -1.83 Million USD | 59.42% |
| 2001 Q1 | -4.51 Million USD | -12.81% |
| 2000 Q2 | -2.42 Million USD | 33.58% |
| 2000 Q1 | -3.64 Million USD | -25.79% |
| 2000 FY | -18.78 Million USD | -66.27% |
| 2000 Q4 | -4 Million USD | 54.01% |
| 2000 Q3 | -8.71 Million USD | -259.51% |
| 1999 Q4 | -2.9 Million USD | -20.83% |
| 1999 Q3 | -2.4 Million USD | 22.58% |
| 1999 Q2 | -3.1 Million USD | -10.71% |
| 1999 Q1 | -2.8 Million USD | 12.5% |
| 1999 FY | -11.3 Million USD | -6.6% |
| 1998 Q1 | -2.4 Million USD | -117.91% |
| 1998 FY | -10.6 Million USD | -1866.67% |
| 1998 Q2 | -2.2 Million USD | 8.33% |
| 1998 Q3 | -2.8 Million USD | -27.27% |
| 1998 Q4 | -3.2 Million USD | -14.29% |
| 1997 Q4 | 13.4 Million USD | 452.63% |
| 1997 Q2 | 4.2 Million USD | 131.82% |
| 1997 Q3 | -3.8 Million USD | -190.48% |
| 1997 FY | 600 Thousand USD | 104.65% |
| 1997 Q1 | -13.2 Million USD | -230.0% |
| 1996 Q1 | -3.4 Million USD | -13.33% |
| 1996 Q4 | -4 Million USD | -42.86% |
| 1996 FY | -12.9 Million USD | -10.26% |
| 1996 Q3 | -2.8 Million USD | -3.7% |
| 1996 Q2 | -2.7 Million USD | 20.59% |
| 1995 Q2 | -2.9 Million USD | 0.0% |
| 1995 Q1 | -2.9 Million USD | 0.0% |
| 1995 Q4 | -3 Million USD | -3.45% |
| 1995 FY | -11.7 Million USD | 0.0% |
| 1995 Q3 | -2.9 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Absci Corporation | -110.56 Million USD | 94.963% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 97.528% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.735% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 44.017% |
| Apollomics, Inc. | -172.6 Million USD | 96.773% |
| 180 Life Sciences Corp. | -19.93 Million USD | 72.064% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 81.495% |
| Bicycle Therapeutics plc | -180.66 Million USD | 96.917% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 92.407% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 96.89% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 79.327% |
| Chimerix, Inc. | -82.09 Million USD | 93.216% |
| CRISPR Therapeutics AG | -153.61 Million USD | 96.375% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 124.511% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 92.134% |
| Fortress Biotech, Inc. | -60.63 Million USD | 90.816% |
| Fortress Biotech, Inc. | -60.63 Million USD | 90.816% |
| Gritstone bio, Inc. | -138.49 Million USD | 95.979% |
| Allakos Inc. | -185.7 Million USD | 97.001% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 88.734% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 95.301% |
| Cytokinetics, Incorporated | -526.24 Million USD | 98.942% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 94.426% |
| Innoviva, Inc. | 179.72 Million USD | 103.099% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 29.016% |
| NLS Pharmaceutics AG | -12.17 Million USD | 54.248% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 95.232% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -44300.364% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 93.827% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 93.261% |
| ImmuCell Corporation | -5.77 Million USD | 3.56% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 95.07% |
| Incyte Corporation | 597.59 Million USD | 100.932% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 95.878% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 16.443% |
| Mustang Bio, Inc. | -51.6 Million USD | 89.208% |
| MiMedx Group, Inc. | 67.43 Million USD | 108.258% |
| MEI Pharma, Inc. | 17.77 Million USD | 131.325% |
| MacroGenics, Inc. | -9.05 Million USD | 38.518% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 33.72% |
| Mereo BioPharma Group plc | -29.46 Million USD | 81.1% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 60.351% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 96.062% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 95.321% |
| Minerva Neurosciences, Inc. | -30 Million USD | 81.44% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 55.341% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 44.9% |
| NextCure, Inc. | -62.72 Million USD | 91.121% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 88.662% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 44.232% |
| Onconetix, Inc. | -37.4 Million USD | 85.113% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 85.894% |
| Opthea Limited | -220.24 Million USD | 97.471% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 89.36% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 89.114% |
| PDS Biotechnology Corporation | -42.94 Million USD | 87.031% |
| Precigen, Inc. | -95.9 Million USD | 94.193% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 77.309% |
| Prime Medicine, Inc. | -198.13 Million USD | 97.189% |
| PureTech Health plc | -65.69 Million USD | 91.523% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 97.732% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.141% |
| Replimune Group, Inc. | -215.79 Million USD | 97.419% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -4531.031% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 77.805% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 69.972% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 98.724% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 77.119% |
| Sesen Bio, Inc. | -19.88 Million USD | 71.993% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.84% |
| Solid Biosciences Inc. | -96.01 Million USD | 94.2% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 97.34% |
| SciSparc Ltd. | -5.12 Million USD | -8.727% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 94.785% |
| TG Therapeutics, Inc. | 12.67 Million USD | 143.947% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 95.226% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 95.001% |
| UroGen Pharma Ltd. | -102.24 Million USD | 94.553% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 91.687% |
| XOMA Corporation | -40.83 Million USD | 86.361% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 98.094% |
| AbCellera Biologics Inc. | -146.39 Million USD | 96.196% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 89.767% |
| Cassava Sciences, Inc. | -97.21 Million USD | 94.272% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 87.514% |
| Precision BioSciences, Inc. | -61.31 Million USD | 90.918% |
| Dyadic International, Inc. | -6.79 Million USD | 18.048% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 47.153% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -494.979% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 80.427% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 95.512% |
| IGM Biosciences, Inc. | -246.41 Million USD | 97.74% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 94.495% |
| Acelyrin, Inc. | -381.64 Million USD | 98.541% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 89.723% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 110.678% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 70.734% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 81.265% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 96.616% |
| Senti Biosciences, Inc. | -92.91 Million USD | 94.007% |
| Mesoblast Limited | -87.95 Million USD | 93.668% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 96.211% |
| ChromaDex Corporation | -4.93 Million USD | -12.778% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -16.227% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 89.275% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 28.554% |
| Seer, Inc. | -86.27 Million USD | 93.545% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 91.055% |
| Novavax, Inc. | -545.06 Million USD | 98.978% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 63.337% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 96.539% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 89.259% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 97.626% |
| Celcuity Inc. | -63.77 Million USD | 91.268% |
| ContextLogic Inc. | -317 Million USD | 98.243% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 97.237% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 93.174% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 101.342% |
| Amarin Corporation plc | -59.11 Million USD | 90.579% |
| AnaptysBio, Inc. | -163.61 Million USD | 96.596% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 68.014% |
| Aptorum Group Limited | -2.82 Million USD | -97.157% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 97.465% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 97.287% |
| Ardelyx, Inc. | -66.06 Million USD | 91.571% |
| Celularity Inc. | -196.29 Million USD | 97.163% |
| Omeros Corporation | -117.81 Million USD | 95.273% |
| Humacyte, Inc. | -110.77 Million USD | 94.973% |
| Immunocore Holdings plc | -55.28 Million USD | 89.927% |
| IO Biotech, Inc. | -86.08 Million USD | 93.531% |
| GT Biopharma, Inc. | -7.59 Million USD | 26.695% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 91.771% |
| Summit Therapeutics Inc. | -614.92 Million USD | 99.094% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 84.152% |
| Pulmatrix, Inc. | -14.12 Million USD | 60.562% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.843% |
| Evogene Ltd. | -23.87 Million USD | 76.678% |
| CorMedix Inc. | -46.33 Million USD | 87.982% |
| BioLineRx Ltd. | -60.61 Million USD | 90.812% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 81.033% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 80.022% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 99.111% |
| scPharmaceuticals Inc. | -54.81 Million USD | 89.839% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 94.279% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 105.247% |
| NLS Pharmaceutics AG | -12.17 Million USD | 54.248% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 77.119% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 96.33% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 84.142% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 73.277% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 94.681% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 92.804% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 90.558% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 68.188% |
| Daré Bioscience, Inc. | -30.16 Million USD | 81.536% |
| bluebird bio, Inc. | -211.91 Million USD | 97.372% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 103.322% |
| DBV Technologies S.A. | -72.72 Million USD | 92.342% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 97.376% |
| Galecto, Inc. | -38.34 Million USD | 85.478% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 83.669% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 88.378% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 97.693% |
| GlycoMimetics, Inc. | -36.89 Million USD | 84.908% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 97.876% |
| ADMA Biologics, Inc. | -28.23 Million USD | 80.279% |
| Clene Inc. | -49.5 Million USD | 88.75% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 98.302% |
| Aptose Biosciences Inc. | -51.2 Million USD | 89.125% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 94.335% |
| Soligenix, Inc. | -6.14 Million USD | 9.31% |
| Century Therapeutics, Inc. | -136.67 Million USD | 95.925% |
| Kura Oncology, Inc. | -152.63 Million USD | 96.351% |
| Surrozen, Inc. | -43.04 Million USD | 87.061% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 93.758% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1084.844% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -878.735% |
| Autolus Therapeutics plc | -208.38 Million USD | 97.328% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 92.254% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 74.299% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 94.544% |
| GRI Bio, Inc. | -13.03 Million USD | 57.283% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -34.693% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 90.447% |
| INmune Bio, Inc. | -30 Million USD | 81.442% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 94.963% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 86.801% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 65.11% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 27.775% |
| Jaguar Health, Inc. | -41.3 Million USD | 86.516% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 64.742% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 90.669% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 82.857% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.983% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 97.659% |
| Verastem, Inc. | -87.36 Million USD | 93.626% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 96.548% |
| Histogen Inc. | -10.62 Million USD | 47.566% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 61.02% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 90.913% |
| Surrozen, Inc. | -43.04 Million USD | 87.061% |
| Organovo Holdings, Inc. | -14.67 Million USD | 62.041% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -9.475% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 33.362% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 96.314% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 88.618% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 46.543% |
| Kronos Bio, Inc. | -112.67 Million USD | 95.057% |
| Turnstone Biologics Corp. | -55.2 Million USD | 89.911% |
| Synaptogenix, Inc. | -6.03 Million USD | 7.775% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 65.64% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 16.694% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 92.862% |
| Exelixis, Inc. | 207.76 Million USD | 102.68% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 96.131% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.947% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 91.361% |
| ESSA Pharma Inc. | -26.58 Million USD | 79.05% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -39.227% |
| Avid Bioservices, Inc. | -140.75 Million USD | 96.043% |
| Insmed Incorporated | -749.56 Million USD | 99.257% |
| MediWound Ltd. | -6.71 Million USD | 17.079% |
| OmniAb, Inc. | -50.61 Million USD | 88.998% |
| Alector, Inc. | -130.39 Million USD | 95.729% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 95.103% |
| Zai Lab Limited | -334.62 Million USD | 98.336% |
| AlloVir, Inc. | -190.41 Million USD | 97.075% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 98.281% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 94.47% |
| Aura Biosciences, Inc. | -76.4 Million USD | 92.711% |
| Immunic, Inc. | -93.61 Million USD | 94.051% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 95.902% |
| Veracyte, Inc. | -74.4 Million USD | 92.515% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 27.445% |
| FibroGen, Inc. | -284.23 Million USD | 98.041% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 78.77% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 107.799% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 20.464% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 70.429% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 75.309% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 111.303% |
| Fortrea Holdings Inc. | -3.4 Million USD | -63.794% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 95.603% |
| XBiotech Inc. | -24.55 Million USD | 77.322% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 91.361% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 96.36% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 85.086% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 91.115% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 94.342% |
| Agenus Inc. | -245.76 Million USD | 97.734% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 74.009% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 89.91% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 99.082% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 91.841% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 97.542% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 74.99% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 95.797% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -5.342% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 77.008% |
| Lantern Pharma Inc. | -15.96 Million USD | 65.11% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 86.19% |
| Ainos, Inc. | -13.77 Million USD | 59.559% |
| Pluri Inc. | -20.88 Million USD | 73.339% |
| Prothena Corporation plc | -147.02 Million USD | 96.212% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 95.109% |
| Rallybio Corporation | -74.56 Million USD | 92.531% |
| Kodiak Sciences Inc. | -260.49 Million USD | 97.862% |
| Cue Biopharma, Inc. | -50.73 Million USD | 89.023% |
| MeiraGTx Holdings plc | -84.02 Million USD | 93.372% |
| Annexon, Inc. | -134.23 Million USD | 95.851% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 90.904% |
| Moderna, Inc. | -4.71 Billion USD | 99.882% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 69.034% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 75.714% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.902% |
| Immix Biopharma, Inc. | -15.42 Million USD | 63.899% |
| CalciMedica, Inc. | -34.35 Million USD | 83.791% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 95.886% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 96.641% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 90.317% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 98.034% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 84.177% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 94.69% |
| Nutriband Inc. | -5.48 Million USD | -1.526% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 86.222% |
| Vor Biopharma Inc. | -117.86 Million USD | 95.275% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.128% |
| Alkermes plc | 355.75 Million USD | 101.565% |
| ProKidney Corp. | -35.46 Million USD | 84.299% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 95.35% |
| Arcellx, Inc. | -70.69 Million USD | 92.122% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 99.134% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 94.526% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 86.439% |
| Atai Life Sciences N.V. | -40.22 Million USD | 86.155% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 93.095% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 92.626% |
| MediciNova, Inc. | -8.57 Million USD | 35.029% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 95.483% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 33.519% |
| GeoVax Labs, Inc. | -25.96 Million USD | 78.553% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 97.672% |
| Biomea Fusion, Inc. | -117.25 Million USD | 95.251% |
| RenovoRx, Inc. | -10.23 Million USD | 45.573% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 96.364% |
| Geron Corporation | -184.12 Million USD | 96.975% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 81.529% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 94.477% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 97.64% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 139.541% |
| Royalty Pharma plc | 1.13 Billion USD | 100.491% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 97.114% |
| Imunon, Inc. | -19.51 Million USD | 71.463% |
| BioAtla, Inc. | -123.46 Million USD | 95.489% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 98.298% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 84.928% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 96.756% |
| Structure Therapeutics Inc. | -89.62 Million USD | 93.786% |
| 89bio, Inc. | -142.18 Million USD | 96.083% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 94.533% |
| aTyr Pharma, Inc. | -50.38 Million USD | 88.948% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 93.648% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 97.657% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 31.178% |
| Akari Therapeutics, Plc | -10 Million USD | 44.355% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -8171.816% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 101.978% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 96.856% |
| Liquidia Corporation | -78.5 Million USD | 92.906% |
| Entera Bio Ltd. | -8.88 Million USD | 37.35% |
| GH Research PLC | -35.58 Million USD | 84.351% |
| Vericel Corporation | -3.18 Million USD | -75.016% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 92.355% |
| Xencor, Inc. | -126.08 Million USD | 95.583% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -47.887% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 65.11% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 73.813% |
| Vaxcyte, Inc. | -402.26 Million USD | 98.616% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 96.947% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 321.961% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 16.443% |
| Portage Biotech Inc. | -75.33 Million USD | 92.608% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 33.519% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 94.238% |
| OncoCyte Corporation | -27.78 Million USD | 79.954% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 58.494% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 49.926% |
| Purple Biotech Ltd. | -19.88 Million USD | 71.987% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 81.116% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 79.554% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 96.984% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 20.658% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 81.293% |
| United Therapeutics Corporation | 984.8 Million USD | 100.565% |
| HilleVax, Inc. | -123.56 Million USD | 95.493% |
| Silo Pharma, Inc. | -3.7 Million USD | -50.486% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 57.397% |
| Pharming Group N.V. | -10.54 Million USD | 47.203% |
| Tharimmune, Inc. | -9.31 Million USD | 40.241% |
| Genprex, Inc. | -30.86 Million USD | 81.954% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 93.369% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 97.64% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 92.453% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -212.514% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -5.155% |
| OKYO Pharma Limited | -16.82 Thousand USD | -32998.649% |
| Savara Inc. | -54.69 Million USD | 89.819% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 72.554% |
| Curis, Inc. | -47.41 Million USD | 88.254% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 63.943% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 81.321% |
| BeiGene, Ltd. | -881.7 Million USD | 99.368% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 92.947% |
| Erasca, Inc. | -125.04 Million USD | 95.546% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -11.369% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -11.369% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 86.132% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 2.195% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 90.778% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 96.062% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 97.106% |
| Adicet Bio, Inc. | -142.65 Million USD | 96.096% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 96.326% |
| Aditxt, Inc. | -32.38 Million USD | 82.802% |
| Adagene Inc. | -18.94 Million USD | 70.607% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 23.835% |
| Quantum-Si incorporated | -95.96 Million USD | 94.197% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 61.798% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 104.208% |
| Compugen Ltd. | -18.75 Million USD | 70.305% |
| Generation Bio Co. | -126.61 Million USD | 95.602% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 92.36% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 93.245% |
| Invivyd, Inc. | -198.64 Million USD | 97.196% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 98.372% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 35.89% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 124.419% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 43.599% |
| 2seventy bio, Inc. | -217.57 Million USD | 97.44% |
| Instil Bio, Inc. | -156.08 Million USD | 96.432% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 75.013% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -29.466% |
| GeoVax Labs, Inc. | -25.96 Million USD | 78.553% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 82.887% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 94.363% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 96.537% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 99.095% |
| Evaxion Biotech A/S | -22.12 Million USD | 74.829% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 93.102% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 97.216% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 91.945% |
| Cingulate Inc. | -23.53 Million USD | 76.337% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 19.43% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 86.029% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 90.641% |
| Clearmind Medicine Inc. | -11.95 Million USD | 53.417% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 91.952% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -219477.877% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 93.517% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 98.509% |
| ImmunityBio, Inc. | -583.19 Million USD | 99.045% |
| Korro Bio, Inc. | -81.17 Million USD | 93.139% |
| Kineta, Inc. | -14.09 Million USD | 60.501% |
| BioVie Inc. | -32.12 Million USD | 82.662% |
| Codexis, Inc. | -76.24 Million USD | 92.695% |
| Celularity Inc. | -196.29 Million USD | 97.163% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 64.601% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 97.404% |
| Virax Biolabs Group Limited | -6.73 Million USD | 17.295% |
| Cibus, Inc. | -267.62 Million USD | 97.919% |
| IN8bio, Inc. | -30 Million USD | 81.441% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 95.247% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 82.345% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 98.48% |
| Eyenovia, Inc. | -27.26 Million USD | 79.572% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 125.793% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -940.935% |
| Elevation Oncology, Inc. | -45.7 Million USD | 87.815% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 92.711% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 86.562% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 95.838% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 81.46% |
| Moolec Science SA | -51.78 Million USD | 89.247% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 89.366% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 86.732% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 95.904% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 86.895% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 37.369% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 73.785% |
| Humacyte, Inc. | -110.77 Million USD | 94.973% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 91.924% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 46.333% |
| Genelux Corporation | -28.29 Million USD | 80.319% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 80.839% |
| Notable Labs, Ltd. | -11.26 Million USD | 50.559% |
| Immunovant, Inc. | -259.33 Million USD | 97.853% |
| Quantum-Si incorporated | -95.96 Million USD | 94.197% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 71.266% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 94.198% |
| Acasti Pharma Inc. | -12.85 Million USD | 56.672% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 75.202% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 85.716% |
| PepGen Inc. | -78.62 Million USD | 92.917% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 74.982% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -16.227% |
| Immuneering Corporation | -53.47 Million USD | 89.585% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -9.475% |
| Belite Bio, Inc | -31.63 Million USD | 82.394% |
| XOMA Corporation | -40.83 Million USD | 86.361% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 89.756% |
| Bionomics Limited | -15.49 Billion USD | 99.964% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 80.9% |
| uniQure N.V. | -308.47 Million USD | 98.195% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 23.835% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 95.488% |
| Forte Biosciences, Inc. | -31.47 Million USD | 82.307% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 32.099% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 80.841% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -940.935% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 78.77% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 66.218% |
| Altimmune, Inc. | -88.44 Million USD | 93.704% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 95.532% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 80.9% |
| Peak Bio, Inc. | -1259.26 USD | -442143.858% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 87.906% |
| Benitec Biopharma Inc. | -21.75 Million USD | 74.397% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 98.356% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 93.287% |
| Zura Bio Limited | -60.36 Million USD | 90.774% |
| PolyPid Ltd. | -23.86 Million USD | 76.665% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 93.287% |
| argenx SE | -295.05 Million USD | 98.113% |
| Immunome, Inc. | -106.8 Million USD | 94.786% |
| Verona Pharma plc | -54.36 Million USD | 89.757% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 94.426% |
| Shattuck Labs, Inc. | -87.29 Million USD | 93.621% |
| CervoMed Inc. | -2.17 Million USD | -156.415% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 58.178% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 87.214% |
| Moolec Science SA | -51.78 Million USD | 89.247% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -32106.147% |
| Design Therapeutics, Inc. | -66.86 Million USD | 91.671% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 93.16% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 85.299% |
| Achilles Therapeutics plc | -69.66 Million USD | 92.006% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -219477.877% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 88.543% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 92.776% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 83.606% |
| MoonLake Immunotherapeutics | -36 Million USD | 84.534% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 86.78% |
| Beam Therapeutics Inc. | -132.52 Million USD | 95.798% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 96.592% |
| AEON Biopharma, Inc. | -52.55 Million USD | 89.404% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 91.532% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 92.22% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 55.497% |
| NeurAxis, Inc. | -14.62 Million USD | 61.926% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.746% |
| Lumos Pharma, Inc. | -34.03 Million USD | 83.637% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 285.091% |
| Palisade Bio, Inc. | -12.3 Million USD | 54.724% |
| Nutriband Inc. | -5.48 Million USD | -1.526% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 95.008% |
| Neurogene Inc. | -36.31 Million USD | 84.666% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 34.49% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 94.326% |
| Athira Pharma, Inc. | -117.67 Million USD | 95.267% |
| HCW Biologics Inc. | -24.99 Million USD | 77.719% |
| XOMA Corporation | -40.83 Million USD | 86.361% |
| Nektar Therapeutics | -276.05 Million USD | 97.983% |
| Arvinas, Inc. | -367.3 Million USD | 98.484% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -8171.816% |
| Merus N.V. | -154.93 Million USD | 96.406% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 94.284% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 82.256% |
| Rezolute, Inc. | -68.45 Million USD | 91.865% |
| Clene Inc. | -49.5 Million USD | 88.75% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 63.893% |
| BeyondSpring Inc. | -21.02 Million USD | 73.514% |
| Synlogic, Inc. | -57.28 Million USD | 90.278% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 53.206% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 48.559% |
| Peak Bio, Inc. | -1259.26 USD | -442143.858% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 85.097% |
| Krystal Biotech, Inc. | 10.93 Million USD | 150.942% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 96.108% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 98.287% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -20.568% |
| MannKind Corporation | -11.93 Million USD | 53.351% |
| Ikena Oncology, Inc. | -68.16 Million USD | 91.83% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 73.5% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 94.008% |
| Gossamer Bio, Inc. | -179.81 Million USD | 96.903% |
| CohBar, Inc. | -11.96 Million USD | 53.445% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 78.405% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 81.529% |
| Legend Biotech Corporation | -518.25 Million USD | 98.925% |
| Mural Oncology plc | -207.44 Million USD | 97.315% |
| Disc Medicine, Inc. | -76.42 Million USD | 92.713% |
| Champions Oncology, Inc. | -7.27 Million USD | 23.461% |
| REGENXBIO Inc. | -263.49 Million USD | 97.886% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 47.527% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 88.277% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 85.338% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 94.44% |
| Vaxart, Inc. | -82.46 Million USD | 93.247% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 1768.549% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 85.166% |
| Cellectis S.A. | -101.05 Million USD | 94.489% |
| Longeveron Inc. | -21.41 Million USD | 73.992% |
| Repare Therapeutics Inc. | -93.79 Million USD | 94.063% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.961% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 92.175% |
| Revolution Medicines, Inc. | -436.36 Million USD | 98.724% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 15.249% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 81.933% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 91.968% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 91.397% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 43.237% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.154% |
| Denali Therapeutics Inc. | -145.22 Million USD | 96.165% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -4531.031% |
| Veru Inc. | -93.15 Million USD | 94.022% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 79.396% |
| Cingulate Inc. | -23.53 Million USD | 76.337% |
| Passage Bio, Inc. | -102.06 Million USD | 94.544% |
| Context Therapeutics Inc. | -23.96 Million USD | 76.761% |
| Exicure, Inc. | -16.91 Million USD | 67.075% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 97.052% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 85.253% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 14.42% |
| Nuvalent, Inc. | -126.21 Million USD | 95.588% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 47.041% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 93.59% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 81.767% |
| OmniAb, Inc. | -50.61 Million USD | 88.998% |
| Anew Medical, Inc. | 1.34 Million USD | 513.706% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 65.291% |
| Lipocine Inc. | -16.35 Million USD | 65.943% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 91.612% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 91.254% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 86.801% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 88.39% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 71.918% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.972% |
| Ocugen, Inc. | -63.07 Million USD | 91.171% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 94.183% |
| Q32 Bio Inc. | -112.96 Million USD | 95.07% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 67.607% |
| Alumis Inc. Common Stock | -154.99 Million USD | 96.407% |
| Equillium, Inc. | -13.33 Million USD | 58.238% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 90.775% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 30.281% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 70.458% |
| Dominari Holdings Inc. | -22.88 Million USD | 75.662% |
| Edesa Biotech, Inc. | -8.37 Million USD | 33.5% |
| vTv Therapeutics Inc. | -20.25 Million USD | 72.499% |
| Bio-Techne Corporation | 168.1 Million USD | 103.313% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 98.418% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 104.322% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 95.429% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 85.321% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 95.056% |
| Nkarta, Inc. | -117.5 Million USD | 95.26% |
| BioCardia, Inc. | -11.57 Million USD | 51.871% |
| Iterum Therapeutics plc | -38.37 Million USD | 85.486% |